Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population

Japanese Journal of Ophthalmology

Volumn 52, Issue 1, 2008, Pages 52-56

  Azad, Raj Vardhan ^a   Khan, Mansur Ali ^a   Chanana, Bhuvan ^a   Azad, Shorya ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE EXAMINATION; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INDIAN; INJECTION SITE BLEEDING; INTERVENTION STUDY; INTRAOCULAR PRESSURE; LINEAR SYSTEM; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOVEA CENTRALIS; HUMANS; INDIA; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 41549158189     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-007-0496-4     Document Type: Article

References (22)

1. Teeters VW, Bird AC. The development of neovascularisation of senile disciform macular degeneration. Am J Ophthalmol 1973;76:1-18.
2. Ryan SJ, Mittl RN, Maumenee AE. The disciform response: an historical perspective. Graefes Arch Klin Exp Ophthalmol 1980;215:1-20.
3. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular photocoagulation study group. Arch Ophthalmol 1991;109:1109-1114.
4. Bressler NM; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
5. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-368.
6. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related macular degeneration. Br J Ophthalmol 1997;81:154-162.
7. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
8. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
9. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
10. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007;143:510-512.
11. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109:1242-1257.
12. Myint K, Armbrecht AM, Mon S, Dhillon B. Transpupillary thermotherapy for the treatment of occult CNV in age-related macular degeneration: a prospective randomized controlled pilot study. Acta Ophthalmol Scand 2006;84:328-332.
13. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP Report No. 5. Arch Ophthalmol 2002;120:1307-1314.
14. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.
15. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
16. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
17. Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007;17:230-237.
18. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-544.
19. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab. Retina 2006;26:262-269.
20. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration. Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
21. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-1513.
22. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421-428.